DINAR SAJAN: Open Payments
NPI 1659536027 · OLDSMAR, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,451 in 117 payments from 13 companies in 2025. Trend: 2023 $4,888 · 2024 $2,694 · 2025 $2,451
Food & beverage: $2,424Speaker / faculty: $27
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 23 | $559 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 16 | $335 |
| Neurocrine BioSciences, Inc. | 13 | $269 |
| E.R. Squibb & Sons, L.L.C. | 13 | $251 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $243 |
| Neuronetics, Inc. | 3 | $173 |
| Teva Pharmaceuticals USA, Inc. | 16 | $167 |
| Lundbeck LLC | 7 | $163 |
| Alkermes, Inc. | 5 | $106 |
| Janssen Pharmaceuticals, Inc | 4 | $93 |
Products named: VRAYLAR, CAPLYTA, INGREZZA, COBENFY, TRINTELLIX, REXULTI, NEUROSTAR TMS THERAPY SYSTEM, AUSTEDO XR.
Industry payments across FL — which companies pay providers there.
